EP3893866A4 - A combination comprising a multiple sclerosis agent and at least one anti-epileptic agent - Google Patents

A combination comprising a multiple sclerosis agent and at least one anti-epileptic agent Download PDF

Info

Publication number
EP3893866A4
EP3893866A4 EP19897521.1A EP19897521A EP3893866A4 EP 3893866 A4 EP3893866 A4 EP 3893866A4 EP 19897521 A EP19897521 A EP 19897521A EP 3893866 A4 EP3893866 A4 EP 3893866A4
Authority
EP
European Patent Office
Prior art keywords
agent
combination
multiple sclerosis
epileptic
epileptic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19897521.1A
Other languages
German (de)
French (fr)
Other versions
EP3893866A2 (en
Inventor
Zafer Toksoz
Ahmet Toksoz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP3893866A2 publication Critical patent/EP3893866A2/en
Publication of EP3893866A4 publication Critical patent/EP3893866A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19897521.1A 2018-12-12 2019-11-15 A combination comprising a multiple sclerosis agent and at least one anti-epileptic agent Withdrawn EP3893866A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2018/19197A TR201819197A2 (en) 2018-12-12 2018-12-12 A combination comprising a multiple sclerosis agent and at least one anti-epileptic agent
PCT/TR2019/050958 WO2020122838A2 (en) 2018-12-12 2019-11-15 A combination comprising a multiple sclerosis agent and at least one anti-epileptic agent

Publications (2)

Publication Number Publication Date
EP3893866A2 EP3893866A2 (en) 2021-10-20
EP3893866A4 true EP3893866A4 (en) 2022-08-03

Family

ID=71076152

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19897521.1A Withdrawn EP3893866A4 (en) 2018-12-12 2019-11-15 A combination comprising a multiple sclerosis agent and at least one anti-epileptic agent

Country Status (3)

Country Link
EP (1) EP3893866A4 (en)
TR (1) TR201819197A2 (en)
WO (1) WO2020122838A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022193723A1 (en) * 2021-03-17 2022-09-22 长沙晶易医药科技有限公司 Composition, preparation method therefor, and use thereof
CN114732797B (en) * 2022-03-31 2023-03-17 海南钧华医疗科技有限公司 Gabapentin and pregabalin compound capsule and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008157408A2 (en) * 2007-06-15 2008-12-24 Xenoport, Inc. Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
WO2009126327A1 (en) * 2008-04-11 2009-10-15 Epiphany Biosciences, Inc. Treatment and/or prevention of multiple sclerosis
WO2018082814A1 (en) * 2016-11-07 2018-05-11 Metriopharm Ag Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11026978B2 (en) * 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008157408A2 (en) * 2007-06-15 2008-12-24 Xenoport, Inc. Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
WO2009126327A1 (en) * 2008-04-11 2009-10-15 Epiphany Biosciences, Inc. Treatment and/or prevention of multiple sclerosis
WO2018082814A1 (en) * 2016-11-07 2018-05-11 Metriopharm Ag Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALLINGTON DOUGLAS ET AL: "New approaches in the management of multiple sclerosis", DRUG DESIGN, DEVELOPMENT AND THERAPY, vol. 4, 22 November 2010 (2010-11-22), pages 343 - 366, XP055931883, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998807/pdf/dddt-4-343.pdf> DOI: 10.2147/DDDT.S9331 *
ELKJAER M L ET AL: "Teriflunomide for multiple sclerosis in real-world setting", ACTA NEUROLOGICA SCANDINAVICA, MUNKSGAARD, COPENHAGEN, DK, vol. 136, no. 5, 20 March 2017 (2017-03-20), pages 447 - 453, XP071063063, ISSN: 0001-6314, DOI: 10.1111/ANE.12755 *
RAFFEL JOEL ET AL: "Multiple sclerosis", MEDICINE - U K EDITION, THE MEDICINE PUBLISHING COMPANY, GB, vol. 44, no. 9, 29 July 2016 (2016-07-29), pages 537 - 541, XP029683929, ISSN: 1357-3039, DOI: 10.1016/J.MPMED.2016.06.005 *
See also references of WO2020122838A2 *

Also Published As

Publication number Publication date
WO2020122838A3 (en) 2020-08-13
EP3893866A2 (en) 2021-10-20
WO2020122838A2 (en) 2020-06-18
TR201819197A2 (en) 2020-06-22

Similar Documents

Publication Publication Date Title
SG11202006626PA (en) Sftd and anr specific reporting
IL283330A (en) Combination compositions comprising a beta-lactamase inhibitor and uses thereof
EP3862352A4 (en) Heteroarylazole compound and pest control agent
EP3779677A4 (en) Software management device
EP3646730A4 (en) Miticide and application thereof
ZA202103580B (en) Aminopeptidase a inhibitors and pharmaceutical compositions comprising the same
EP3760616A4 (en) 4-methyldihydropyrimidinone compound and medicinal use thereof
EP3893866A4 (en) A combination comprising a multiple sclerosis agent and at least one anti-epileptic agent
EP3847011A4 (en) A lamitube and implementations thereof
EP4049159A4 (en) Ransomware prevention
EP3950010A4 (en) Continuous decontamination device
EP3861720A4 (en) Non-intrusive 360 view without camera at the viewpoint
AU2019253650A1 (en) Phenoxyurea compound and pest control agent
EP3778563A4 (en) Phenoxyurea compound and pest control agent
EP3927131A4 (en) Component type management device
EP4069850A4 (en) Compositions comprising a nuclease and uses thereof
EP3742034C0 (en) Hose assembly and use
EP3901146A4 (en) Phenylpyrrolidine compound and use thereof
EP3849620A4 (en) Dithiolsaccharide mucolytic agents and uses thereof
EP3853213A4 (en) Shielding agents and their use
EP3769759A4 (en) Epilepsy treatment agent
EP3794883A4 (en) Ranging between devices
EP3810274A4 (en) A combination comprising fingolimod and at least one anti-epileptic agent
EP4039328A4 (en) Dysuria-alleviating agent
EP3993874A4 (en) Cd38-binding agents and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210712

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220706

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20220630BHEP

Ipc: A61K 9/00 20060101ALI20220630BHEP

Ipc: A61P 25/28 20060101ALI20220630BHEP

Ipc: A61P 25/08 20060101ALI20220630BHEP

Ipc: A61P 25/00 20060101ALI20220630BHEP

Ipc: A61K 31/4409 20060101ALI20220630BHEP

Ipc: A61K 31/44 20060101ALI20220630BHEP

Ipc: A61K 31/277 20060101ALI20220630BHEP

Ipc: A61K 31/195 20060101ALI20220630BHEP

Ipc: A61K 31/197 20060101AFI20220630BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230207